GSK to acquire Sierra Oncology for $1.9B to bolster specialty meds; Sierra soars 38%

Apr. 13, 2022 4:47 AM ETGSK plc (GSK)By: Ravikash, SA News Editor

word M and A made with wood building blocks, concept

Maks_Lab/iStock via Getty Images

GlaxoSmithKline (NYSE:GSK) is acquiring San Mateo, Calif.-based Sierra Oncology (NASDAQ:SRRA) in a $1.9B cash deal to bolster its cancer drug portfolio.

Under the agreement, outstanding shares of Sierra will be cancelled and converted into the right to

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.